Value of Information Methods for NHLBI Trials

NHLBI 试验的信息方法的价值

• 批准号: 9050702
• 负责人: ANIRBAN BASU
• 金额: $ 67.21万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-04-15 至 2019-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9050702
• 关键词: Accounting; Acute; Area; Binding; Blood; Clinical; Clinical Trials; Communication; Computer software; Decision Making; Disease; Economics; Educational workshop; Expert Opinion; Face; Funding; Goals; Health; Heart; Heart Diseases; Hematological Disease; Imagery; Intervention; Investments; Knowledge; Literature; Lung; Lung diseases; Medical; Meta-Analysis; Methods; Modeling; National Heart, Lung, and Blood Institute; Online Systems; Outcome; Participant; Patient-Focused Outcomes; Plant Roots; Population; Process; Randomized Clinical Trials; Reporting; Research; Research Personnel; Risk; Sample Size; Science; Southwest Oncology Group; Testing; Time; Translating; Uncertainty; Work; base; cancer clinical trial; clinical decision-making; design; experience; improved; models and simulation; novel strategies; population health; prospective; systematic review; theories; tool; user-friendly

 DESCRIPTION (provided by applicant): NHLBI faces major challenges in determining how best to allocate investment in randomized clinical trials (RCTs). Currently, there is no consistent mechanism to evaluate and compare proposed RCTs for NHLBI to best determine where to invest its limited dollars. Novel approaches in decision science can provide valuable information to enhance the RCT prioritization process at NHLBI. The overall objective of this project is to develop a comprehensive toolkit of pragmatic value of information (VOI) approaches and the corresponding software that can be readily used by clinical researchers and funders in order to assess the value of RCTs related to heart, lung and blood diseases. In addition, we will develop standardized tables that would report each component of these calculations for an RCT to improve transparency and communication of the results. Using these methods, one can estimate the value of a perfect study that would eliminate all uncertainty and be translated immediately. Such an estimate would provide an upper bound to the value of the RCT. Alternatively; one can estimate the value of an RCT with a proposed design that would partially eliminate uncertainty. In other applications, one can derive optimal sample sizes or compare alternative designs (e.g. adaptive versus traditional) for a proposed study. Such information and presentations of expected risk and value from different RCT investments can help NHLBI with a quantitative visualization of its investment portfolio and optimize that portfolio over time.

 描述（由适用提供）：NHLBI在确定如何最好地分配随机临床试验（RCT）方面面临重大挑战。目前，没有一致的 评估和比较NHLBI提议的RCT的机制，以最好地确定在何处投资其有限的美元。决策科学中的新方法可以提供有价值的信息，以增强NHLBI的RCT优先序列。该项目的总体目的是开发一个务实的信息价值（VOI）方法的全面工具包，以及临床研究人员和资金可以很容易地使用的相应软件，以评估与心脏，肺和血液疾病有关的RCT的价值。此外，我们将开发标准化表，以报告这些计算的每个组件以提高结果的透明度和交流。使用这些方法，可以估计一项完美研究的价值，该研究将消除所有不确定性并立即翻译。这样的估计将提供与RCT值的上限。或者;一个人可以用建议的RCT估算RCT的价值。设计将部分消除不确定性。在其他应用中，可以得出最佳样本量或比较拟议的研究的替代设计（例如自适应与传统）。从不同的RCT投资中的预期风险和价值的此类信息和介绍可以帮助NHLBI定量可视化其投资组合，并随着时间的推移优化该投资组合。